Novel oxadiazole functionalized pyridopyrimidine derivatives; their anticancer activity and molecular docking studies

Abstract

A series of novel oxadiazole functionalized pyridopyrimidine derivatives prepared starting from 6‐methyl/ethyl‐2‐oxo‐4‐(trifluoromethyl)‐1,2‐dihydropyridine‐3‐carbonitrile 1. This compound 1 on reaction with sulfuric acid obtained compound 2, further compound 2 on reaction with chloroacetamide followed by reaction with ethoxy methylene malonic diethyl ester coupling and further cyclization to obtain compound 5. Compound 5 on reaction with hydrazide hydrate obtained hydrazide derivatives 6. Compound 6 on reaction with diverse substituted aromatic acids to get oxadiazole derivatives 7a–l. All the final compounds 7a–l evaluated for anticancer activity against four human cancer cell lines such as HeLa—cervical cancer (CCL‐2); COLO 205—colon cancer (CCL‐222); HepG2—liver cancer (HB‐8065); and MCF7—breast cancer (HTB‐22) and promising compounds 7d and 7k have been identified and evaluated for molecular docking interactions.